Market Research Future published a half cooked research report on “Global Actinic Keratosis Treatment Market Research Report – Forecast to 2022” Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.
Cancer is becoming one of the major problems across the globe. In more than 90% cases skin cancer is caused due to exposure to ultraviolet radiation from the sun. There are three major type of skin cancer namely basal cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. Exposure to the radiation during childhood can cause melanomas and basal-cell cancers. People with light skin are at higher risk for skin cancer.
Also known as solar keratosis, actinic keratosis is a type of skin cancer in which the skin gets rough and develops scaly patches as a result of exposure to the sun. It’s most commonly found on face, lips, ears, back of hands, forearms, and scalp or neck.
The global skin cancer market is driven by increasing prevalence of skin cancer, rising healthcare expenditure in developing economies and increasing government support. While adverse effect associated with treatment, long approval time for the drugs and strict regulatory rules has restrained the growth of the market.
Get a sample report at https://www.marketresearchfuture.com/sample_request/2366 .
Key Players in the Actinic Keratosis Market:
LEO Pharma Inc., Clinuvel Pharmaceuticals Ltd, Biofrontera AG, DUSA Pharmaceuticals, Inc., TOLMAR Pharmaceuticals, Inc., Valeant, Galderma S.A., Perrigo Company plc. are key player in the market. Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
Developments of key players:
Galderma is a global leader in dermatology and has strategic partnerships with brands like Soolantra, Tri-Luma, Loceryl, BenzacEpiduo, Oracea, Differin, Mirvaso, Cetaphil, Excipial, Daylong, Restylane, Emervel and many other brands. The company focus on the production of innovative solutions in the field of dermatology for the treatment of various skin diseases such as acne, rosacea, psoriasis, steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and other various fields in skin care.
According to the World Health Organization (WHO), the prevalence of skin cancer is increasing at a rate of 6.52%. Beside this continuous increasing demand for better treatment and increasing government support for R&D has provided fuel for the growth of market.
According to the American Academy of Dermatology (AAD), skin diseases affects one in every fourth American. The prevalence of skin diseases is also found to be increasing in Canada. According to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime.
Browse complete report at https://www.marketresearchfuture.com/reports/actinic-keratosis-treatment-market-2366 .
January 2017: Galderma launched two new dermal fillers. In December, Galderma received FDA approval for a pair of next-generation hyaluronic acid (HA) dermal fillers: Restylane Refyne and Restylane Defyne.
January 2017: Galderma announces approval of Azzalure in Europe for treatment of lateral canthal lines in adults. Azzalure, a product in-licensed from Ipsen, received positive opinion from the French regulatory authority, ANSM, for treatment of lateral canthal lines (crow’s feet), either alone or in combination with treatment of Glabellar lines.
July 2016: Chugai and Galderma Announce Global License Agreement for Nemolizumab (CIM331), Novel Biologic for Skin Diseases. The primary aim of this agreement is to improve atopic dermatitis by breaking the itch-scratch cycle which has great expectation for Nemolizumab.
January 2016: Maruho and Galderma to Join Forces in a Strategic Alliance in Japan. One of the major reasons of this strategic alliance is that Galderma will permit Maruho to additionally promote their products in japan in the field of dermatology of medicines for infectious disease, which include systemic fungal infections.
Actinic Keratosis Treatment Market in Asia Pacific Expected to Exhibit Fastest Growth:
Asia Pacific is the fastest growing market for actinic keratosis treatment market due to large patients’ population and growing geriatric population. China and India drive the major market and contribute largest share in the Asia Pacific actinic keratosis treatment market. Rapidly developing technology and increasing treatment methods are driving the growth of the market.
According to survey carried out by Pfizer, in 2012, 6.7 million of cancer cases was registered in Asia Pacific region which will increasing continuously. Additionally, according to the American Cancer Society, in 2015, 4.2 newly diagnosed invasive cancer cases were registered in China.
According to World Health Organization (WHO), the prevalence of skin cancer is increasing at a rate of 6.52% in Asia Pacific. Beside this continuous increasing demand for better treatment and increasing government support for R&D has provided fuel for the growth of market.
Market Research Future
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312